| Literature DB >> 18194452 |
J Mages1, K Freimüller, R Lang, A K Hatzopoulos, S Guggemoos, U H Koszinowski, H Adler.
Abstract
BACKGROUND: Diseases caused by gammaherpesviruses continue to be a challenge for human health and antiviral treatment. Most of the commonly used antiviral drugs are directed against viral gene products. However, the emergence of drug-resistant mutations ma limit the effectiveness of these drugs. Since viruses require a host cell to propagate, the search for host cell targets is an interesting alternative.Entities:
Mesh:
Substances:
Year: 2008 PMID: 18194452 PMCID: PMC2673020 DOI: 10.1111/j.1582-4934.2008.00235.x
Source DB: PubMed Journal: J Cell Mol Med ISSN: 1582-1838 Impact factor: 5.310
Fig 1Overview of the general changes in expression values upon murine gammaherpesvirus 68 (MHV-68) infection. (A) Barplot showing the mean percentage of Affymetrix present calls for the three arrays of one condition, respectively. The present call is an indication for the reliability of detection of a probe set. Standard deviation is shown based on three array replicates. (B) Boxplots representing the normalized log2 expression values of all 12,488 transcripts present on the arrays, averaged per condition, for the three BL/6-derived cells, mock and MHV-68 infected, respectively. (C) Venn diagram describing the partitioning and overlap of the 231 significantly up-regulated probe sets among the three cellular systems. (D) Diagram as in C for the 965 significantly down-regulated probe sets. (E) Hierarchical Clustering of the average fold-changes induced by the viral infection. The 231 transcripts clustered are significantly different in at least one cell type with a fold-change >2 compared to the respective mock-treated cells. Red colour indicates up-regulation, green colour down-regulation after virus infection. ANA, Ana-1 macrophages; ENDO, embryonic endothelial progenitor cells or eEPCs; MEF, primary mouse embryonic fibrob-lasts; all cell types are of BL/6 genetic background.
Functional analysis of the 231 significantly up-regulated transcripts upon MHV-68 infection. (A) Analysis of overrepresentation of gene categories for induced transcripts. Gene categories were assigned to the list of 231 up-regulated genes with the program EASE. The probability of seeing the number of ‘List Hits' in the ‘List Total’, given the frequency of ‘Population Hits' in the ‘Population Total’, is calculated by the Fisher exact probability and the P-values are shown in the last column. (B) Selected genes were manually assigned to functional biological categories. For each of the three cell lines, the average fold-change (FC) is shown.
| A | ||||||
|---|---|---|---|---|---|---|
| System | Gene category | List hits | List total | Population hits | Population total | Probability |
| Defense response | 45 | 168 | 629 | 7516 | 7*10−13 | |
| Innate immune response | 17 | 168 | 146 | 7516 | 2*10−08 | |
| Chemotaxis | 13 | 168 | 95 | 7516 | 2*10−07 | |
| Interferon induction | 7 | 130 | 27 | 5351 | 3*10−06 | |
| Chemokine receptor binding activity | 7 | 170 | 30 | 7550 | 3*10−06 | |
| Cytokine activity | 15 | 170 | 177 | 7550 | 1*10−05 | |
| MHC I | 4 | 130 | 10 | 5351 | 6*10−05 | |
| Antiviral response protein activity | 5 | 170 | 24 | 7550 | 1*10−04 | |
Fig 2Common and unique changes in gene expression comparing BL/6 and Balb/c-derived MEF cells. (A) Venn diagram and heat map showing the 36 transcripts that are significantly up-regulated in either BL/6 or Balb/c MEF cells. The heat map is based on fold-changes. Red colour indicates up-regulation, green colour down-regulation after MHV-68 infection. (B) Venn diagram of the 2698 transcripts that are significantly down-regulated in MEF cells.
Fig 3Validation of microarray data by RT-PCR. Total RNA derived from infected or non-infected cells was reverse-transcribed, and the resulting cDNA was amplified using gene-specific primers. RT-PCR products were separated by electrophoresis in 2% agarose gels and visualized by ethidium bromide staining. Upward- and downward-pointing arrows indicate up- and down-regulation, whereas ‘=’ indicates that the expression was unchanged. In all cases, RT-PCRs were consistent with the microarray data. ANA, Ana-1 macrophages; ENDO, embryonic endothelial progenitor cells or eEPCs; MEF, primary mouse embryonic fibroblasts
Fig 4Effect of siRNA-mediated gene silencing on MHV-68 yield. NIH3T3 cells (A, C, D, F and G), MEF cells (B) and Vero cells (E) were transfected with 50 pmoles of the indicated siRNAs. 24 hrs (A-E) or 72 hrs (F and G) after transfection, cells were infected with MHV-68 with an MOI of 1 (A-F) or 0.1 (G). After 60 min. at 37°C, the inoculum was removed and fresh medium was added. Cells and supernatants were either harvested 48 hrs (A-E) or 72 hrs (F and G) after infection, and RNA was isolated and analysed by RT-PCR (A). Virus titres were determined by plaque assay (B-G). In panel A, down-regulation of synaptobrevin-like 1 (sybl1) by siRNA1 directed against sybl1 is shown on the left, and down-regulation of Lman1 by siRNAQ12 directed against Lman1 is shown on the right. Different concentrations of cDNA template, as indicated on top of each panel, were amplified by PCR with primer pairs specific for sybl1 and Lman1, respectively. A primer set for the housekeeping gene GAPDH was used in parallel for PCR amplification as a control. In panels B-G titres are expressed as percentages of the virus yield, where 100% represents the titre of virus grown in wells transfected with control siRNA. In panels B-G, values are means ± SD from three independent experiments. The asterisks indicate a statistically significant difference with P<0.003 (Student's t-test). In panels F and G, data from single experiments are shown.
Fig 5Effect of pharmacological phospholipase A2 (PLA2) inhibition on MHV-68 yield. NIH3T3 cells in 6-well plates were pre-incubated at 4°C for 30 min. and infected with MHV-68 at an multiplicity of infection (MOI) of 0.1. After the incubation period of 60 min. at 4°C to allow virus adsorption, inocula were removed and temperature was shifted to 37°C in the presence or absence of 50 μM of the phospholipase A2 (PLA2) inhibitor 2-(p-amylcinnamoyl)amino-4-chlorobenzoic acid (ONO-RS-082), dissolved in ethanol. Viral titers were determined after 48 hrs by plaque assay on BHK-21 cells. Values are means – SD from three independent experiments. The asterisk indicates a statistically significant difference with P = 0.0000011 (Student's t-test).
Fig 6Effect of siRNA on herpes simplex virus 1 (HSV-1). Vero cells were transfected with 50 pmoles of siRNA1 directed against sybl1. 24 hrs after transfection, cells were infected with HSV-1 at an MOI of 1. After 60 min. at 37°C, the inoculum was removed and fresh medium was added. Cells and supernatants were harvested 48 hrs after infection, and virus titres were determined by plaque assay. Titres are expressed as percentages of the virus yield, where 100% represents the titre of virus grown in wells transfected with control siRNA. Values are means ± SD from three independent experiments. The asterisk indicates a statistically significant difference with P= 0.0007 (Student's t-test).
| GAPDH: | 5′primer: CTCACTCAAGATTGTCAGCAATG |
| 3′primer: GAGGGAGATGCTCAGTGTTGG | |
| CD14: | 5′primer: CCTGGAATACCTTCTAAAGCGTGTG |
| 3′primer: CCCTTGTTGCCCACGACACGTTGC | |
| TGFβR3: | 5′primer: GTCTTCTCTGTGGCAGAGAATGAGC |
| 3′primer: CTAGAGAGGTGCAGGCGTCGTCAGG | |
| Sybl1: | 5′primer: TGGAAACCACCAAACTTATGACCTG |
| 3′primer: CAGTTCAACTTGGTAATGGATAAAC | |
| CCL3: | 5′primer: TTCTCAGCGCCATATGGAGCTGACAC |
| 3′primer: GAGATGGAGCTATGCAGGTGGCAGG | |
| Wisp1: | 5′primer: TACACATCAAGGCAGGGAAGAAATG |
| 3′primer: CATGGAACTTTACCCTGAGCCACAC | |
| Lman1: | 5′primer: GGTGCAGACAGTGTTGTTCGTTGG |
| 3′primer: GTGCTGTGACACTTCTAGGATAAATGC | |
| Irg1: | 5′primer: CAATATCTAAACGAGTTGCACTGG |
| 3′primer: GTGTATTTCATAGGGGTACAGTC |
| B | ||||||
|---|---|---|---|---|---|---|
| Classification | Probe set | Gene symbol | Gene title | MEF FC | ANA FC | ENDO FC |
| 9754_f_at | H2-D1 | Histocompatability 2, D region locus 1 | −2.1 | 1.1 | 2.1 | |
| 99378_f_at | H2-D1 | Histocompatability 2, Q region locus 1 | −1.4 | 1.3 | 2.0 | |
| 98472_at | H2-T23 | Histocompatability 2, T region locus 23 | −1.3 | 2.4 | −1.1 | |
| 99379_f_at | LOC676689 | Similar to H-2 class I histocompatability antigen. L-D a chain precursor | −1.6 | 1.3 | 2.1 | |
| 93085_at | Psmb9 | Proteosome (prosome, macropain) subunit, β type 9 | 1.0 | 1.1 | 2.4 | |
| 100154_at | Tapbp | TAP binding protein | −1.9 | 1.4 | 3.1 | |
| 102736_at | Ccl2 | Chemokine (C-C motif) ligand 2 | −6.0 | 3.8 | −1.0 | |
| 94146_at | Ccl4 | Chemokine (C-C motif) ligand 4 | 7.7 | 3.0 | 1.2 | |
| 94761_at | Ccl7 | Chemokine (C-C motif) ligand 7 | −24.7 | 4.8 | −1.1 | |
| 96953_at | Cxcl14 | Chemokine (C-X-C motif) ligand 14 | −7.7 | 1.1 | 3.7 | |
| 101160 at | Cxcl2 | Chemokine (C-X-C motif) ligand 2 | 2.2 | 2.9 | −1.1 | |
| 98240_at | ll12rb1 | Interleukin 12 receptor, β 1 | −1.6 | 2.7 | 2.4 | |
| 94755_at | ll1a | Intrleukin 1 α | 10.3 | 1.0 | 1.0 | |
| 103486_at | ll1b | Interleukin 1 β | 11.3 | 1.6 | 1.5 | |
| 93871_at | ll1m | Interleukin, receptor antagonist | −1.1 | 3.1 | 1.6 | |
| 102629_at | Tnf | Tumour necrosis factor | 5.1 | 1.2 | −1.0 | |
| 98088_at | Cd14 | CD14 antigen | 1.6 | 2.7 | 5.5 | |
| 94747_at | Csf2rb1 | Colony stimulating factor 2 receptor β 1 | 7.1 | 1.4 | 1.1 | |
| 101800_at | Fpr-rs2 | Formyl peptid receptor, related sequence 2 | 7.2 | 1.0 | −1.2 | |
| 99387_at | Fpr1 | Formyl peptide receptor 1 | 3.1 | 1.0 | 1.1 | |
| 95585_at | Proc | Protein C | −1.5 | 2.2 | 1.6 | |
| 98018_at | procr | Protein C receptor, endothelial | 3.4 | 2.2 | −1.1 | |
| 98406_at | Ccl5 | Chemokine (C-C motif) ligand 5 | 3.6 | 6.7 | −1.0 | |
| 98822_at | Isg15 | ISG15 ubiquitin-like modifier | −4.1 | 1.7 | 6.6 | |
| 98466_r_at | Ifi204 | Interferon activated gene 204 | −2.9 | 3.1 | 1.1 | |
| 100013_at | Ifi35 | Interferon-induced protein 35 | −2.6 | 1.7 | 3.8 | |
| 100981_at | Ifit1 | Interferon-induced protein with tetratricopeptide repeats 1 | −6.0 | 1.2 | 7.9 | |
| 93956-at | Ifit3 | Interferon-induced protein with tetratricopeptide repeats 3 | −2.5 | 1.3 | 3.8 | |
| 160253_at | Ifitm3 | Interferon induced transmembrane protein 3 | −1.9 | 1.6 | 3.3 | |
| 161699_i_at | Irf6 | Interferon regulatory factor 6 | 1.0 | 1.1 | 2.2 | |
| 104669_at | Irf7 | Interferon regulatory factor 7 | 1.2 | 6.9 | 1.5 | |
| 97409-at | Irgm | immunity-related GTpase family, M | −6.1 | 2.0 | 2.7 | |
| 103432_at | Isg20 | Interferon-stimulated protein | −4.1 | −1.0 | 6.0 | |
| 102717_at | Oas1g | 2'5' oligoadenylate synthetase 1G | −1.4 | 2.3 | 3.9 | |
| 101465_at | Stat1 | single transducer and activator of transcription 1 | −3.9 | 1.4 | 2.4 | |
| 97507_at | Lgals3bp | Lectin, galactoside-binding, soluble, 3 binding pro-tein | −2.2 | 2.4 | 2.1 | |
| 102974_at | Marco | macrophage receptor with collagenous structure | 6.2 | 1.1 | −1.1 | |